Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Lirilumab in Relapsed Resectable SCCHN
NCT03341936Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
A Phase 2 trial of lirilumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Dana-Farber Cancer Institute. Started Mar 2018; status: active, not recruiting.
02
Drugs
lirilumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03341936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341936.